InnoCare, a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 in China.
InnoCare discovered and developed the oral drug candidate ICP-332. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway in T cells, playing an important role in the pathogenesis of inflammatory diseases. Currently no selective TYK2 inhibitor has been approved globally.
ICP-332 is a potent and selective TYK2 inhibitor with 400 folds of selectivity against JAK2 to avoid the adverse events associated with non-selective JAK inhibitors. ICP-332 will be used to treat psoriasis and other T cell related autoimmune diseases.
Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnnoCare said, “ICP-332 is an innovative drug candidate for the treatment of autoimmune diseases. We are committed to our core value of ‘Science-driven innovation for the benefit of patients’, and will work closely with top clinical experts to rapidly advance clinical trial to benefit patients.”